The questions that remain unanswered include the actual prevalence of sexual side effects (we do not know if it affects 5 percent or 30 percent of women), whether certain doses are more likely to cause sexual dysfunction than others, whether compounded semaglutide formulations produce different sexual side effect profiles than brand-name versions, whether specific pharmacy sources or compounding pharmacies produce formulations with different tolerability profiles, and whether pre-treatment screening can identify women at higher risk for sexual dysfunction on GLP-1 agonists
While it is effective for these purposes, it can also affect the digestive system, leading to symptoms of GERD
Reproductive function in a population of young faroese men with elevated exposure to polychlorinated biphenyls (PCBs) and perfluorinated alkylate substances (PFAS)
For tirzepatide, the gap is even larger at starting doses
Taking both simultaneously increases side effect risk without improving efficacy and is not supported by any clinical evidence
Growth hormone secretagogues: Biology and clinical potential